Pink slips have followed the green light at Entrada Therapeutics. | Pink slips have followed the green light at Entrada ...

The EC has granted orphan drug designation to Dyne Therapeutics’ DYNE-251 for treating Duchenne muscular dystrophy (DMD).

The orphan drug designation is particularly noteworthy as it can provide Dyne with a range of benefits, including reduced regulatory fees, assistance with clinical protocols, eligibility for research ...

Dyne Therapeutics (DYN) announced that the European Commission has granted orphan drug designation for DYNE-251 for the treatment of Duchenne ...

Detailed price information for Dyne Therapeutics Inc (DYN-Q) from The Globe and Mail including charting and trades.

Prosensa has already attempted to strengthen its future marketing position by filing blocking patents on the use of exon-51-skipping therapies to treat DMD in the EU, noted Sanyal. "We believe ...

Pet owners have been warned skipping vaccinations could pose their ... taking their pet to the vet (51%) due to the cost. Some 2,000 pet owners were surveyed as part of the study.

However, postoperative immunohistochemical examination confirmed the diagnosis of BA. Next-generation sequencing (NGS) further revealed an EGFR exon 19 deletion mutation. Conclusion: The histological ...

BOULDER, Colo. (AP) — Two-way star Travis Hunter apparently has decided to skip Colorado's pro day with the Heisman Trophy winner projected to be a top-3 pick in the NFL draft later this month.

The company is also working on programs based on exons 51, 52, 45, and 44. Altogether ... Wave says it plans to submit clinical trial applications for other exon-skipping therapies in 2026.